SS-31 (Elamipretide) and Cardiolipin: Membrane Research

SS-31 cardiolipin research illustrates how a peptide's proposed mechanism can shift as better biophysical tools arrive: from a general radical-scavenging description toward a model centered on lipid binding and membrane surface charge. This article traces the chemistry of the Szeto-Schiller series, the evidence that SS-31 associates with cardiolipin in the inner mitochondrial membrane, the cross-linking data on nearby proteins, and how laboratories typically set up experiments with the peptide.

The lipid at the center of the story

Cardiolipin is structurally unusual: a dimeric glycerophospholipid bearing two phosphate groups and four acyl chains. It is synthesized within the inner mitochondrial membrane and remodeled by the transacylase tafazzin. Two properties make it relevant here:

• Charge. The two phosphates give cardiolipin an anionic headgroup region, so membranes enriched in it present a strongly negative surface potential.
• Shape. Its conical geometry favors regions of high curvature, which is why cardiolipin is associated with cristae architecture and with binding sites on respiratory-chain complexes, ATP synthase and carrier proteins.

Cardiolipin also participates in the membrane association of cytochrome c. Peroxidase chemistry at the cardiolipin-cytochrome c interface has been described as a route by which the lipid becomes oxidized, and this interface is the point at which SS-31 studies converge [1, 2].

Chemistry of the Szeto-Schiller series

The SS peptides were developed by Hazel Szeto and Peter Schiller from an opioid-peptide scaffold, retaining an alternating basic-aromatic pattern [1]:

Position	Residue	Contribution
1	D-Arg	Basic; D-configuration resists proteolysis
2	Dmt (2',6'-dimethyltyrosine)	Aromatic phenol
3	Lys	Second basic residue
4	Phe-NH2	Aromatic; amidated C-terminus

The 2004 characterization of this series described the peptides as cell-permeable and reported that they concentrate strongly in the inner mitochondrial membrane, and that analogs lacking the Dmt residue behaved differently in assays of mitochondrial swelling and radical production [1]. That structure-activity contrast is why the dimethyltyrosine residue has stayed in the pharmacophore across the series.

From cardiolipin binding to surface electrostatics

The fluorescent-analog study

Birk and colleagues examined how SS-31 interacts with mitochondria using a polarity-sensitive fluorescent analog of the peptide. They reported high-affinity association with cardiolipin, and reported that the peptide-lipid complex reduced the peroxidase activity attributed to cardiolipin-bound cytochrome c in their assays [2]. Working in a rat kidney ischemia model, the same paper linked peptide exposure to preservation of cristae morphology and faster ATP recovery in the tissue studied; the authors framed cardiolipin interaction as the upstream event [2].

The biophysics study

Mitchell and colleagues then took SS-31 into model membranes with defined lipid compositions [3]. Their findings sharpened the model considerably:

1. SS-31 partitions into the interfacial region of the bilayer rather than inserting deeply into the acyl core.
2. Binding affinity and lipid binding density scale with membrane surface charge, consistent with electrostatic attraction to anionic lipids.
3. Even at high occupancy, SS-31 did not destabilize lamellar bilayers, although it produced saturable changes in lipid packing.
4. The peptide altered surface electrostatics of both model and mitochondrial membranes, and changed the interfacial distribution of divalent cations such as calcium [3].

That last point offers a mechanism that does not require any redox chemistry at all: a cationic peptide adsorbed at an anionic interface changes the local electric field, and therefore the distribution of ions and of peripheral basic proteins. Molecular dynamics simulations of mitochondria-targeted tetrapeptides have been used to explore the same electrostatic effects computationally [4].

The protein interaction landscape

Chavez and colleagues applied chemical cross-linking with mass spectrometry to mitochondria exposed to SS-31 [5]. Every protein they recovered as an SS-31 interactor was a known cardiolipin binder, and the set fell into two functional groups: oxidative phosphorylation machinery and enzymes of 2-oxoglutarate metabolism. Cross-linked residues frequently lay near regions implicated in cardiolipin binding [5]. The natural reading is that SS-31 occupies the lipid-protein interface rather than a classical binding pocket.

Designing SS-31 experiments

Researchers working with the peptide encounter a recurring set of methodological questions.

Choose the right membrane system. Model liposomes with defined cardiolipin content let you vary surface charge systematically, which is the variable the biophysical work identified as decisive [3]. Isolated mitochondria preserve native protein composition but confound lipid and protein contributions.

Separate electrostatics from redox chemistry. Useful comparators include:

• Analogs lacking Dmt, which were reported to behave differently in the original series characterization [1].
• Charge-matched control peptides with non-phenolic aromatics.
• Liposomes in which cardiolipin is replaced by another anionic lipid such as phosphatidylglycerol, to test charge dependence versus cardiolipin specificity.

Watch the ionic conditions. Since binding is charge-driven, buffer ionic strength and divalent cation content are not incidental details. Report them, and hold them constant across arms.

Confirm what is in the vial. The Dmt residue is non-standard, and its presence should be visible in the exact mass. Confirm identity by LC-MS before biophysical work, as described in our article on mass spectrometry and peptide identity confirmation; lot-level analytical data for our catalog is posted on the lab reports page.

Typical readouts

Question	Assay
Does the peptide bind the membrane?	Tryptophan/Dmt fluorescence, isothermal titration calorimetry, liposome partitioning
Does surface potential change?	Zeta potential, electrochromic probes, fluorescent pH/charge reporters at the interface
Is bilayer order altered?	Fluorescence anisotropy, differential scanning calorimetry, small-angle X-ray scattering
Are bioenergetics affected?	Oxygen consumption in isolated mitochondria, membrane potential dyes, ATP synthesis assays
Who is nearby?	Cross-linking mass spectrometry, as in the 2020 interactor study [5]

Where SS-31 sits among mitochondrial research tools

SS-31 is unusual in acting on the lipid phase rather than on a receptor or enzyme. That makes it complementary to other compounds discussed on this blog: MOTS-c is studied as a signaling peptide acting through AMPK and nuclear gene expression, while thiol chemistry and glutathione status, covered in our glutathione redox overview, govern the soluble antioxidant capacity of the same compartment. Studies that combine a membrane-acting peptide with a soluble redox readout can distinguish interface effects from bulk redox effects.

Elamipretide has been evaluated in clinical trials; in a laboratory context the relevant literature is the biophysical and mitochondrial work described above.

Key takeaways

• SS-31 is D-Arg-Dmt-Lys-Phe-NH2, an amphipathic cationic tetrapeptide from the Szeto-Schiller series [1].
• A fluorescent-analog study reported high-affinity cardiolipin binding and reduced cardiolipin-cytochrome c peroxidase activity in assays [2].
• Model-membrane work showed interfacial partitioning that scales with surface charge, with saturable packing changes and altered surface electrostatics [3].
• Cross-linking mass spectrometry recovered only cardiolipin-binding proteins as SS-31 interactors, in oxidative phosphorylation and 2-oxoglutarate metabolism groups [5].
• Because binding is electrostatic, cardiolipin content, ionic strength and divalent cations must be controlled and reported.

This article summarizes published research for informational purposes. All Ascent Sciences products are for laboratory research use only and are not for human or animal consumption.

References

1. Zhao K, Zhao GM, Wu D, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Journal of Biological Chemistry. 2004;279(33):34682-34690. PubMed
2. Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. 2013;24(8):1250-1261. PubMed
3. Mitchell W, Ng EA, Tamucci JD, et al. The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. Journal of Biological Chemistry. 2020;295(21):7452-7469. PubMed
4. Tamucci JD, Alder NN, May ER. Peptide power: mechanistic insights into the effect of mitochondria-targeted tetrapeptides on membrane electrostatics from molecular simulations. Molecular Pharmaceutics. 2023;20(12):6114-6129. PubMed
5. Chavez JD, Tang X, Campbell MD, et al. Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences USA. 2020;117(26):15363-15373. PubMed